References
- Brown M S, Goldstein J L. A receptor mediated pathway for cholesterol homeostasis. Science 1986; 232: 34–47
- Breslow J L. Apolipoprotein genetic variation and human disease. Physiol Rev 1988; 68: 85–132
- Lusis A J. Genetic factors affecting blood lipoproteins: the candidate gene approach. J Lipid Res 1988; 29: 397–429
- Soria L F, Ludwig E H, Clarke H RG, Vega G L, Grundy S M, McCarthy B J. Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B‐100. Proc Natl Acad Sci USA 1989; 86: 587–91
- Humphries S E. DNA polymorphisms of the apolipoprotein genes—their use in the investigation of the genetic component of hyperlipidaemia and atherosclerosis. Atherosclerosis 1988; 89–108
- Zannis V I, Breslow J L. Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification. Biochemistry 1981; 20: 1033–41
- Müller C. Xanthomata, hypercholesterolemia, angina pectoris. Acta Med Scand Suppl 1938; 89: 75–84
- Yamamoto T, Davis C G, Brown M S, Schneider W J, Casey M L, Goldstein J L, Russell D W. The human LDL receptor: acysteine‐rich protein with multiple Alu sequences in its mRNA. Cell 1984; 39: 27–38
- Lehrman M A, Schneider W J, Brown M S, Davis C G, Elhammer A, Russell D W, Goldstein J L. The Lebanese allele at the low density lipoprotein receptor locus: nonsense mutation produces truncated receptor that is retained in endoplasmic reticulum. J Biol Chem 1987; 262: 401–10
- Aalto‐Setälä K, Helve E, Kovanen P T, Kontula K. The Finnish type of LDL receptor gene mutation (FH‐Helsinki) deletes exons encoding the carboxy‐terminal part of the receptor and creates an internalization‐defective phenotype. J Clin Invest 1989; 84: 499–506
- Hobbs H H, Brown M S, Russell D W, Davignon J, Goldstein J L. Deletion in the gene for the low‐density‐lipoprotein receptor in a majority of French Canadians with familial hypercholesterolemia. N Engl J Med 1987; 317: 734–7